ID   Dami
AC   CVCL_4360
SY   DAMI
DR   BTO; BTO:0001550
DR   ATCC; CRL-9792
DR   BioSample; SAMN03151657
DR   CCRID; 3131C0001000700068
DR   Cosmic; 1191696
DR   KCB; KCB 200782YJ
DR   Lonza; 1426
DR   Wikidata; Q54828561
RX   Patent=US5128245;
RX   PubMed=3196874;
RX   PubMed=9166871;
RX   PubMed=9326259;
RX   PubMed=10508494;
RX   PubMed=11021758;
RX   PubMed=12592342;
RX   PubMed=20143388;
WW   https://www.atcc.org/support/faqs/fd471/DAMI%20ATCC%20CRL9792-1071.aspx
WW   http://iclac.org/wp-content/uploads/Cross-Contaminations_v10_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a HEL derivative (PubMed=9166871; PubMed=9326259; PubMed=10508494; PubMed=12592342; PubMed=20143388). Originally thought to originate from the peripheral blood of a 57 year old male patient with megakaryoblastic leukemia.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00116.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met133Lys (c.398T>A); Zygosity=Homozygous (from parent cell line).
CC   Discontinued: ATCC; CRL-9792; true.
CC   Derived from sampling site: Peripheral blood.
ST   Source(s): ATCC; CCRID
ST   Amelogenin: X (CCRID)
ST   Amelogenin: X,Y (ATCC)
ST   CSF1PO: 10
ST   D13S317: 9,11
ST   D16S539: 11
ST   D18S51: 12,16
ST   D19S433: 11,13
ST   D21S11: 29,31.2
ST   D2S1338: 18,19
ST   D3S1358: 15
ST   D5S818: 11
ST   D7S820: 7
ST   D8S1179: 13,15
ST   FGA: 22,23
ST   TH01: 7
ST   TPOX: 11
ST   vWA: 14,17
DI   NCIt; C7152; Erythroleukemia
DI   ORDO; Orphanet_318; Acute erythroid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0001 ! HEL
SX   Male
AG   30Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 20-05-21; Version: 25
//
RX   Patent=US5128245;
RA   Greenberg S.M., Handin R.I.;
RT   "Establishment, characterization and differentiation of a new
RT   megakaryocytic cell line, the Dami cells.";
RL   Patent number US5128245, 07-Jul-1992.
//
RX   PubMed=3196874; DOI=10.1182/blood.V72.6.1968.1968;
RA   Greenberg S.M., Rosenthal D.S., Greeley T.A., Tantravahi R.,
RA   Handin R.I.;
RT   "Characterization of a new megakaryocytic cell line: the Dami cell.";
RL   Blood 72:1968-1977(1988).
//
RX   PubMed=9166871; DOI=10.1182/blood.V89.11.4238;
RA   Handin R.I.;
RT   "DAMI cell line.";
RL   Blood 89:4238-4238(1997).
//
RX   PubMed=9326259; DOI=10.1182/blood.V90.7.2850;
RA   MacLeod R.A.F., Dirks W.G., Drexler H.G.;
RT   "Early contamination of the Dami cell line by HEL.";
RL   Blood 90:2850-2851(1997).
//
RX   PubMed=10508494; DOI=10.1002/(SICI)1097-0215(19991112)83:4<555::AID-IJC19>3.0.CO;2-2;
RA   MacLeod R.A.F., Dirks W.G., Matsuo Y., Kaufmann M., Milch H.,
RA   Drexler H.G.;
RT   "Widespread intraspecies cross-contamination of human tumor cell lines
RT   arising at source.";
RL   Int. J. Cancer 83:555-563(1999).
//
RX   PubMed=11021758; DOI=10.1038/sj.leu.2401891;
RA   Majka M., Rozmyslowicz T., Honczarenko M., Ratajczak J., Wasik M.A.,
RA   Gaulton G.N., Ratajczak M.Z.;
RT   "Biological significance of the expression of HIV-related chemokine
RT   coreceptors (CCR5 and CXCR4) and their ligands by human hematopoietic
RT   cell lines.";
RL   Leukemia 14:1821-1832(2000).
//
RX   PubMed=12592342; DOI=10.1038/sj.leu.2402799;
RA   Drexler H.G., Dirks W.G., Matsuo Y., MacLeod R.A.F.;
RT   "False leukemia-lymphoma cell lines: an update on over 500 cell
RT   lines.";
RL   Leukemia 17:416-426(2003).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//